National Advisory Panel

Chair and Medical Director, erectile hall
   Alfred N. Poindexter, III, MD

Advisory Panel Members
   Susan A. Ballagh, MD
   Paul Blumenthal, MD, MPH
   PonJola Coney, MD
   Paula J. Adams Hillard, MD
   Catherine M. Lynch, MD
   Susan Wysocki, RNC, NP

Contributing Editors
   Frank C. Stanzyk, PhD
   Rob A. Wild, MD, MPH




Susan A. Ballagh, MD, has been assistant professor in the Department of Obstetrics and Gynecology at the Eastern Virginia Medical School in Norfolk and a member of CONRAD (Contraceptive Research and Development) since 1997. Prior to that, Dr. Ballagh was assistant professor in the Department of Obstetrics and Gynecology at the Stanford University Medical Center (1992-1997). During the same period, she was chief of Women’s Health at the Department of Veterans Affairs, Palo Alto.

Usually serving as principal investigator, Dr. Ballagh has participated in many clinical trials. The areas of study have been contraception, menopause, and women’s health conditions including endometriosis, osteoporosis and incontinence. She has addressed the same subjects in numerous lectures, articles, abstracts and book chapters. Dr. Ballagh serves on the National Medical Advisory Board for Planned Parenthood and is an ad hoc reviewer for grant applications for the National Institutes of Health. She also serves as an ad hoc reviewer for Contraception, Fertility and Sterility, and the Journal of Adolescent Gynecology.

Dr. Ballagh received her medical degree from Drew/UCLA Medical Education Program at the University of California at Los Angeles in 1986. She completed a residency in obstetrics and gynecology in 1990 and a fellowship in reproductive endocrinology and contraception in 1992 at Los Angeles County/University of Southern California Medical Center. She is board certified in reproductive endocrinology and obstetrics and gynecology.

Prior to her medical training, Dr. Ballagh was a WIC nutritionist, completing her didactic internship and master’s degree in nutrition at the University of Wisconsin at Madison.

Dr. Ballagh is engaged in research for Barr Laboratories, Berlex Laboratories, Conceptus, Inc., Eli Lilly, Pharmacia/Pfizer, Galen/Warner-Chilcott, Organon, Watson Pharmaceuticals and Wyeth Pharmaceuticals. She serves on the speakers’ bureaus of AHRP, Berlex Laboratories, Cardinal Health, Inc., Council on Hormone Education, Galen/Warner-Chilcott, Health Learning Systems, Organon, Inc., Ortho Pharmaceutical Corporation and Wyeth Pharmaceuticals. Dr. Ballagh is a consultant for Galen/Warner-Chilcott and Gerson-Lehrman Group.

Paul Blumenthal, MD, MPH, has been associate professor of Obstetrics and Gynecology at Johns Hopkins University, Baltimore, Maryland, since 1995. During the same period, he has served as director of the university’s Fellowship Program in Family Planning Clinical Care and Research and an associate in its Population Center. In 1999, he became medical director of the Cervical Cancer Prevention Project, a collaborative effort with the JHPIEGO Corporation ( A Johns Hopkins Program for Training In Reproductive Health). He has been a member of the Johns Hopkins University faculty since 1990.

Since 1988, he has been a consultant to several international programs administered by JHPIEGO, International Projects Assistance Services (IPAS), and Family Health International (FHI). Involving numerous countries in Africa, the former Soviet Union, and Southeast Asia, the consultations have concerned the introduction of reproductive health technology and training and curriculum development in obstetrics and gynecology.

From 1987 to 1988, he was co-director of the Uro-Gynecology Program at Michael Reese Hospital and Medical Center in Chicago, Illinois. From 1984 to 1988, he was assistant professor in the Department of Obstetrics and Gynecology at the University of Chicago Pritzker School of Medicine. From 1989 through 1990 he was a visiting lecturer at the University of Nairobi and Kenyatta National Hospital in Nairobi Kenya.

Active in research, he is currently leading studies of oral, barrier, and implant contraceptive methods and visual inspection of the cervix in detecting and preventing cervical cancer. He is also studying the use of mifepristone and misoprostol in medical abortions and reproductive health training and contraceptive and sterilization services in the developing world.

He was medical director of Planned Parenthood in Maryland from 1994 to 2001 and has been a member of the National Medical Committee of the Planned Parenthood Federation of America since 1996. In 2000, he was special advisor to the World Health Organization on the development of technical guidelines for program managers in abortion care.

He received his medical degree from The University of Health Sciences/ The Chicago Medical School in 1977 and completed a residency in obstetrics and gynecology at the Michael Reese Hospital and Medical Center in 1982. In 1984, he undertook an additional residency in the Department of Preventive Medicine and a fellowship in reproductive epidemiology at the University of California at Los Angeles.

Dr. Blumenthal is engaged in research for Berlex, Barr and the Gates Foundation. He is a consultant for USAID, WHO, JHPIEGO, and IPAS and a member of the speakers’ bureau for Berlex and Organon.


PonJola Coney, MD, is senior vice president for Health Affairs and dean of the School of Medicine at Meharry Medical College in July 2002. Dr. Coney earned her medical degree at the University of Mississippi Medical Center and completed a residency at the University of North Carolina-Chapel Hill. She developed successful infertility treatment programs during her tenure at the University of Oklahoma, University of Nebraska and University of Arizona.

A leader in reproductive medicine, Dr. Coney’s research interests have focused on menopausal health, contraception and assisted reproduction. She came to Meharry from Southern Illinois University School of Medicine, where she served since 1995 as professor and chair of the department of obstetrics and gynecology. She has over 40 publications in medical literature.

A founding director of the Society for Executive Leadership in Academic Medicine, Dr. Coney is active in numerous professional organizations. Her appointment is historic for the Hedwig van Amerigen Executive Leadership in Academic Medicine program (ELAM), a national group formed to advance women in the ranks of medicine. Her appointment at Meharry represented a significant accomplishment for women in academic medicine when she became the first of ELAM's inaugural class to ascend to the position of dean of a medical school.

Dr. Coney is engaged in research for Wyeth.



Paula J. Adams Hillard, MD, has taught at the University of Cincinnati College of Medicine in Ohio since 1984, becoming professor of Obstetrics and Gynecology in 1997 and professor of Pediatrics in 2000. From 1981 to 1984, she was assistant professor of Obstetrics and Gynecology at the University of Virginia in Charlottesville. During the same period, she was the university’s director of Ambulatory Obstetrics and Gynecology.

Her research interests include ambulatory obstetrics and gynecology, primary care gynecology and adolescent gynecology, including contraceptive methods and compliance. In addition, she has studied sexually transmitted diseases as well as sexual abuse and domestic violence.

She is a member of the editorial boards of several journals, including The Contraception Report, Contemporary Ob/Gyn, and the Journal of Pediatric and Adolescent Gynecology. She is also associate editor of Novak’s Gynecology and the author of numerous book chapters on women’s health. From 1982 to 1989, she wrote a monthly column for Parent’s magazine on pregnancy and birth. In 1997, she was named by Good Housekeeping magazine as one of the “Best Doctors for Women.”

She has been an oral examiner for the American Board of Obstetrics and Gynecology for 13 years. She is past Chair of the Committees on Patient Education and Adolescent Health of the American College of Obstetrics and Gynecology (ACOG), past vice-chair of the Committee on Gynecologic Practice. She is currently the Chair of the Guidelines for Women’s Health Committee. She has also represented ACOG on the Committee on Adolescents of the American Academy of Pediatrics.

In 1977, she obtained her medical degree from Stanford University School of Medicine in Palo Alto, California, and completed her residency in obstetrics and gynecology at the University of North Carolina in Chapel Hill in 1981.

Dr. Hillard is engaged in research for Berlex and Wyeth Pharmaceuticals. She is a consultant and advisory board member for Proctor and Gamble. She is a member of the speakers' bureaus at Pharmacia-Upjohn, 3-M Pharmaceuticals, Pfizer, Organon, Ortho-McNeill, Barr Labs and Wyeth Pharmaceuticals.


Catherine M. Lynch, MD, has been associate professor of Obstetrics and Gynecology at the University of South Florida in Tampa since 1994. During the same period, she has also served as the university’s director of the Division of General Obstetrics and Gynecology. In addition, she is co-medical Director of the Women’s Cancer Screening Center at the Tampa General Hospital.

Her research interests encompass general obstetrics and gynecology, contraceptive and hormonal therapy, urogynecologic surgery and urodynamics, and pelvic reconstruction.

She received her medical degree from the University of South Florida College of Medicine in 1990 and completed her residency at the same college in 1994.

Dr. Lynch is engaged in research for Wyeth. She is a member of the speakers' bureaus at Wyeth, Pfizer and Berlex.


Alfred N. Poindexter, III, MD, received his medical degree in 1968 from Meharry Medical College in Nashville, Tennessee and completed a residency in obstetrics and gynecology at the University of Missouri, Kansas City General Hospital in 1972. In addition, he completed a post-doctoral fellowship in reproductive endocrinology at the Baylor College of Medicine in 1976.

Dr. Poindexter has been a faculty member at Baylor since 1975. He is director of the Division of Contraceptive Research and Development, Director of Gynecological Services in the Baylor Population Program, and Director of the Reproductive Endocrinology Service at the University of Houston. He is also chairman of Baylor's Affirmative Action Committee. Dr. Poindexter also holds clinical appointments at four hospitals in Houston.

Dr. Poindexter has been a board examiner for the American Board of Obstetrics and Gynecology since 1988 and is currently an ad hoc member of the editorial boards of the New England Journal of Medicine, American Journal of Obstetrics and Gynecology, Fertility and Sterility, and Obstetrics and Gynecology. He has been a member of the Board of Directors and was secretary of the Planned Parenthood Federation of America.

Dr. Poindexter has participated in numerous studies concerning the efficacy of contraceptive drugs, devices, and programs, often serving as principal investigator. His current research focuses on tubal sterilization and a new spermicidal agent. Past research has covered oral and vaginal contraceptives.

Dr. Poindexter is engaged in research for Columbia Labs, Organon, Ortho-McNeil and Wyeth Pharmaceuticals. He is a consultant for Wyeth Pharmaceuticals, Zonagena and Organon and a member of the speakers' bureaus for Johnson & Johnson, Ortho-McNeil and Wyeth.


Frank Z. Stanczyk, PhD, is professor of Research at the University of Southern California School of Medicine in Los Angeles, holding that position in the Department of Obstetrics and Gynecology since 1994 and in the Department of Preventive Medicine since 1999. He has been a member of the medical school faculty since 1986.

From 1983 to 1986, he was associate scientist at the Oregon Regional Primate Research Center in Beaverton and associate professor in the Department of Obstetrics and Gynecology at the Oregon Health Sciences University in Portland. He held assistant professorships in obstetrics and gynecology at the same university from 1980 to 1984 and at the University of Southern California from 1975 to 1980. The latter university was also the site of a postdoctoral research fellowship in obstetrics and gynecology from 1972 to 1974.

His research interests include the pharmacokinetics and metabolism of estrogens, progestins and androgens in postmenopausal women, the effect of contraceptive steroids on androgens, and the role of steroid hormones in the etiology of Alzheimer’s disease, lupus erythematosis, multiple sclerosis, and prostate, ovarian, and breast cancer. Current projects include the effect of exogenous DHEA on serum levels of DHEA, its major metabolites, and cardiovascular and skeletal markers in postmenopausal women, and the effect of steroid hormones on cognitive function and mood in women during the menstrual cycle, pregnancy, and postpartum, as well as in men and women with Alzheimer’s disease.

He has authored or co-authored almost 200 articles and 200 abstracts (published or in preparation) on progestins, estrogens, and other steroid hormones. In addition, he has been associate editor of Contraception since 1991, and a member of the editorial boards of Steroids and the Journal of the Society of Gynecologic Investigation since 1995.
He received his doctoral degree in experimental medicine from McGill University in Montreal, Quebec in 1972.

Dr. Stanczyk has no relationships to disclose.


Robert A. Wild, MD, MPH, is professor and chief of Reproductive Endocrinology and Infertility in the Department of Obstetrics and Gynecology, and adjunct professor of Medicine (Cardiology) and Biostatistics and Epidemiology at the University of Oklahoma City Health Sciences Center in Oklahoma City. He is an experienced clinician and investigator with a focus on primary prevention strategies for women through a combination of obstetrics and gynecology, preventive cardiology, and public health practices.

Dr. Wild is a graduate of the University of Missouri School of Medicine. He completed his residency in obstetrics and gynecology at the Boston Hospital for Women, Harvard Medical School. In 1998, he received a Master's of Public Health degree in clinical epidemiology and biostatistics from the University of Oklahoma Health Sciences Center. He is a diplomat of the National Board of Medical Examiners and of the American Board of Obstetrics and Gynecology (reproductive endocrinology subspecialty). He is an examiner for the American Board of Obstetrics and Gynecology (general and reproductive endocrine).

Dr. Wild is past President of Preventive Cardiology, the Society of Reproductive Endocrinologists, and the Oklahoma City Obstetrical and Gynecological Society. He is the only gynecologist to have received a Preventive Cardiology Award from the National Heart, Lung, and Blood Institute. He is on the advisory board for the Office of Research on Women's Health (ORWH) at the National Institutes of Health.

Dr. Wild's research interests include primary prevention strategies for women, with a focus on the heart, reproductive endocrinology (polycystic ovary syndrome and endometriosis), sex steroids, and cardiovascular diseases.

Dr. Wild has no relationships to disclose.



Susan Wysocki, RNC, NP, is the President and CEO of the National Association of Nurse Practitioners in Women's Health (NPWH). She is a woman's health nurse practitioner certified by the National Certification Corporation (NCC) and is a nationally recognized speaker and opinion leader in the field of women's health.

Ms. Wysocki is the editor of Clinical Challenges in Women's Health: A Handbook for Nurse Practitioners. She is the Editor of Women's Health Care: A Practical Journal for Nurse Practitioners and Conversations in Counseling. Further, she is a contributing editor and Washington, DC bureau chief for Nurse Practitioner World News. Ms. Wysocki also serves on the editorial boards of the American Journal for Nurse Practitioners, Dialogues in Contraception, and the Contraceptive Technology Update. She has authored numerous articles in nursing publications.

In 1999, Ms. Wysocki was selected by a national panel of nurse practitioners convened by the Nurse Practitioner Journal for a Lifetime Achievement Award. In 2000, she was chosen as a charter Fellow of the American Academy of Nurse Practitioners. She has served as the Chair of the National Alliance of Nurse Practitioners and was the founding president of the American College of Nurse Practitioners.

Ms. Wysocki is a graduate of Boston College School of Nursing and attained her certificate as a nurse practitioner through the New Jersey College of Medicine and Dentistry and the Planned Parenthood Federation of America.

Ms. Wysocki is on the advisory boards at Ortho-McNeil, Berlex, Pfizer (Parke-Davis), Wyeth, 3M Corporation, Pharmacia, Solvay, and Novavax. She serves on the speakers' bureaus for Ortho-McNeil, Wyeth, Berlex, Organon, Pharmacia, and Pfizer (Parke-Davis).




Baylor College of Medicine The Center for Collaborative and Interactive Technologies